Organon (OGN) Goodwill & Intangibles (2020 - 2026)
Organon (OGN) recorded quarterly Goodwill & Intangibles of $5.3 billion in Q1 2026, down 0.59% quarter-over-quarter from $5.3 billion in Q4 2025, and up 11.01% on a YoY basis from $4.7 billion in Q1 2025.
Organon (OGN) Goodwill & Intangibles (2020 - 2026) Analysis & Trends
Organon's Goodwill & Intangibles history runs 7 years deep, the most recent figure standing at $5.3 billion for Q1 2026.
- In Q1 2026, Goodwill & Intangibles rose 11.01% year-over-year to $5.3 billion; the TTM figure through Mar 2026 stood at $5.3 billion (up 11.01% YoY), while the FY2025 annual figure was $5.3 billion, down 13.31% from the prior year.
- Goodwill & Intangibles was $5.3 billion for Q1 2026 at Organon, down from $5.3 billion in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $29.1 billion in Q4 2023 to a low of $4.7 billion in Q3 2025.
- Historically, Goodwill & Intangibles has averaged $6.6 billion across 5 years, with a median of $5.3 billion in 2022.
- The sharpest annual moves came in 2023 and 2024: Goodwill & Intangibles soared 454.53% in 2023, then plunged 79.08% in 2024.
- A 5-year view of Goodwill & Intangibles shows it stood at $5.3 billion in 2022, then jumped by 454.53% to $29.1 billion in 2023, then slumped by 79.08% to $6.1 billion in 2024, then declined by 13.31% to $5.3 billion in 2025, then retreated by 0.59% to $5.3 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $5.3 billion (Q1 2026), $5.3 billion (Q4 2025), and $4.7 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.25 Bn |
| Dec 31, 2025 | 5.28 Bn |
| Sep 30, 2025 | 4.71 Bn |
| Jun 30, 2025 | 6.04 Bn |
| Mar 31, 2025 | 4.73 Bn |
| Dec 31, 2024 | 6.09 Bn |
| Sep 30, 2024 | 4.72 Bn |
| Jun 30, 2024 | 5.29 Bn |
| Mar 31, 2024 | 4.82 Bn |
| Dec 31, 2023 | 29.12 Bn |
| Sep 30, 2023 | 5.16 Bn |
| Jun 30, 2023 | 5.20 Bn |
| Mar 31, 2023 | 5.22 Bn |
| Dec 31, 2022 | 5.25 Bn |
| Sep 30, 2022 | 5.27 Bn |
| Jun 30, 2022 | 5.24 Bn |
| Mar 31, 2022 | 5.27 Bn |
| Dec 31, 2021 | 5.25 Bn |
| Sep 30, 2021 | 5.29 Bn |
| Jun 30, 2021 | 5.31 Bn |